Content Conference Coverage Conferences ICAAC 2015
ICAAC 2015: No Transmission of Integrase Inhibitor-Resistant HIV Seen in California Patients
- Details
- Category: HIV Treatment
- Created on Sunday, 11 October 2015 00:00
Not one case of transmission of HIV that is resistant to any of the integrase inhibitor drugs has been seen among newly diagnosed patients in a database of resistance tests in California, according to a presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)last month in San Diego.
Coverage of 2015 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Details
- Category: HIV Treatment
- Created on Tuesday, 06 October 2015 00:00
HIVandHepatitis.com coverage of the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, September 17-21, 2015.
Highlights of this year's conference include experimental antiretroviral drugs and treatment strategies, HIV prevention, and comorbidities among people with HIV and HIV/HCV coinfection.
10/6/15
ICAAC 2015: Combination Vaginal Ring May Be Able to Prevent Both HIV and Herpes
- Details
- Category: Microbicides
- Created on Friday, 25 September 2015 00:00
An experimental silicone vaginal ring with separate compartments may be able to deliver both tenofovir for prevention of HIV infection and acyclovir for prevention of genital herpes and potentially other sexually transmitted infections (STIs), according to a report at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last weekin San Diego.
ICAAC 2015: New Antiretrovirals and HIV Treatment Strategies
- Details
- Category: HIV Treatment
- Created on Friday, 25 September 2015 00:00
Researchers presented findings from several HIV studies at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Diego, including an overview of the START treatment initiation study, an all-women antiretroviral therapy trial, and studies of a better tolerated version of tenofovir (tenofovir alafenamide or TAF) and the experimental integrase inhibitor cabotegravir.
ICAAC 2015: New Hepatitis C NS5A Inhibitor Looks Promising in Early Studies
- Details
- Category: Experimental HCV Drugs
- Created on Friday, 25 September 2015 00:00
A new hepatitis C virus (HCV) NS5A inhibitor being developed by Enanta -- EDP-239 -- was well-tolerated and demonstrated promising antiviral activity against genotype 1 HCV in a single-dose monotherapy study presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Diego.
Web Design and Development by